• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Cloud Pharmaceuticals receives $150,000 phase I grant from NSF SBIR

Cloud Pharmaceuticals receives $150,000 phase I grant from NSF SBIR

July 30, 2014
CenterWatch Staff

Cloud Pharmaceuticals, a therapeutics company focused on cloud-based drug design and development, has been awarded a phase I grant from the National Science Foundation Small Business Innovation Research (NSF SBIR) program. The grant is valued at $150,000.

This phase I NSF SBIR project focuses on advancing the development of the Inverse Design computational drug discovery platform. Inverse Design runs computational models to quickly scan vast molecular space to find the strongest inhibitors of specific biological targets. It uses advanced quantum mechanics/molecular mechanics calculations for binding accuracy combined with an artificial intelligence heuristic search algorithm.

"We intend to apply the grants to add tools to enhance the molecular searching functionality of our Inverse Design platform," said Dr. Shahar Keinan, chief scientific officer for Cloud Pharmaceuticals. "The first is a multi-object optimization to further enhance the accuracy of our search results. The second is an automated scaffold-design algorithm that enables highly selective inhibitor designs. These tools will further our efforts to identify molecules that not only bind well to a biological target, but also feature good clinical properties and demonstrate low probability of toxic and off-target side effects, as well as greater stability and synthesizability."

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing